Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer

Abstract excerpt

Abstract Chromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions) have been clinically validated as oncogenic drivers in a wide range of human cancers. Typically, NTRK gene fusions involve both inter- and intrachromosomal fusions of the 5′ regions of a variety of genes with the 3′ regions of NTRK genes leading to TRK fusion proteins with constitutive, ligand-independent activation of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Lung Cancer Treatments and Mutations
• Share to Melanoma and MAPK Pathways